The Delaware chancellor ruled Wednesday that Boston Scientific Corp. failed to show that Channel Medsystems Inc. had misrepresented aspects of its business in a way that significantly affected the companies’ $275 million merger, meaning Boston Scientific will have to complete the deal…

Read this piece in its entirety at Law360.